XORTX Cash Flow To Debt Ratio from 2010 to 2025

XRTX Stock  USD 0.92  0.09  10.84%   
XORTX Therapeutics Cash Flow To Debt Ratio yearly trend continues to be fairly stable with very little volatility. Cash Flow To Debt Ratio is likely to outpace its year average in 2025. During the period from 2010 to 2025, XORTX Therapeutics Cash Flow To Debt Ratio regression line of annual values had significance of  0.0005 and arithmetic mean of (140.17). View All Fundamentals
 
Cash Flow To Debt Ratio  
First Reported
2010-12-31
Previous Quarter
(657.74)
Current Value
(624.86)
Quarterly Volatility
241.6671138
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 996.5 K, Other Operating Expenses of 5.8 M or Total Operating Expenses of 5.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.88. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.
  
Check out the analysis of XORTX Therapeutics Correlation against competitors.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Latest XORTX Therapeutics' Cash Flow To Debt Ratio Growth Pattern

Below is the plot of the Cash Flow To Debt Ratio of XORTX Therapeutics over the last few years. It is XORTX Therapeutics' Cash Flow To Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XORTX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash Flow To Debt Ratio10 Years Trend
Slightly volatile
   Cash Flow To Debt Ratio   
       Timeline  

XORTX Cash Flow To Debt Ratio Regression Statistics

Arithmetic Mean(140.17)
Coefficient Of Variation(172.41)
Mean Deviation179.25
Median(0.87)
Standard Deviation241.67
Sample Variance58,403
Range658
R-Value(0.77)
Mean Square Error25,406
R-Squared0.59
Significance0.0005
Slope(39.12)
Total Sum of Squares876,045

XORTX Cash Flow To Debt Ratio History

2025 -624.86
2024 -657.74
2023 -571.95
2020 -113.87
2019 -4.91
2018 -35.96
2017 0.33

About XORTX Therapeutics Financial Statements

XORTX Therapeutics investors use historical fundamental indicators, such as XORTX Therapeutics' Cash Flow To Debt Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in XORTX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Flow To Debt Ratio(657.74)(624.86)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.